Meinox
  • Home
  • Technology
    • Pipeline
    • Publications
    • Patents
    • MEISi Products
    • RUO Products >
      • MEISi-1
      • MEISi-2
      • hCAIIi-1
      • hCAIIi-2
      • hCAIIi-3
      • Meinox Small Molecule Library
      • Pathonex
      • ProteinX
  • News
  • About Us
    • Careers
    • Investors
    • Partners
  • Contact

hCA-II inhibitor-3 (hCAIIi-3)

Description: hCA-II inhibitor-3
Synonyms: hCA-II inhibitor-3 , hCAIIi-3, ​CA-II inhibitor, carbonic anhydrase inhibitor, Small molecule inhibitor-3 of human carbonic anhydrase-II enzyme 
SMILES: S=C3S/C(=C/c1c(F)cccc1Cl)C(=O)N3CCc2ccc(cc2)S(N)(=O)=O

Purity: ≥95% (HPLC)
Compound ID: Mx00891
Picture
Cat. Number
Packsize
Availability
Pricing
​hCAIIi-3-5mg
5 mg
In stock
​Inquire
​hCAIIi-3-10mg
10 mg
In stock
​Inquire
​hCAIIi-3-25mg
25 mg
​In stock
​Inquire

Applications

Carbonic anhydrase (CA) enzymes are zinc‐containing metalloenzymes that maintain pH homeostasis, and they catalyze the CO2 hydration. hCAs are involved in different physiological as well as pathological processes. In humans, they are divided into 16 isoform forms varying according to tissue distribution and cellular localization (cytosol, membrane, and mitochondria). CA isoforms play a role in a number of biological processes, including acid–base balance control, tumorigenicity, ureagenesis, gluconeogenesis, bone resorption, and calcification. Thus, they are considered a well-established therapeutic target for treatment of a wide range of pathological disorders.
​

Proprietary tools and expertise in both biology and chemistry were used to develop novel hCA-II inhibitors. In silico, in vitro assays were used to validate small molecule hCA-II inhibitors. The enzyme inhibition activity of newly synthesized compounds on carbonic anhydrase (II) was evaluated. It was found that the IC50 values new molecules were in nanomolar level and much smaller than those of sulfanilamide (reference compound, IC50 of 3.5 μM). hCAIIi-3 was among the most potent carbonic anhydrase (II) inhibitor with the low IC50 value.

Technical Data

Property
Description
M. Wt
456.97
SMILES
S=C3S/C(=C/c1c(F)cccc1Cl)C(=O)N3CCc2ccc(cc2)S(N)(=O)=O
Storage
−20°C
Purity
​≥95% (HPLC)
Form
Powder
Gene Information
​Carbonic anhydrase (CA) enzymes. Among these, CA I–III, CA VII, and CA XIII are cytosolic enzymes; CA VA and CA VB are located in the mitochondria; CA IV, CA IX, CA XII, and CA XIV are membrane‐bounding enzymes; and CA VI takes place in saliva and milk.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis. MEINOX products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

-
​Solvent
Max Conc. mg/mL
​Max Conc. mM
​Solubility
DMSO
>10 
100
​Solubility
Water
Not determined
Not determined
​Solubility
PBS
​Not determined
Not determined

Safety Information

Safety Information
Description
​Personal Protective Equipment 

Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
RIDADR
NONH for all modes of transport

Product Data Sheets

Certificate of Analysis / Product Datasheet
Safety Datasheet (MSDS)
 Terms & Conditions
Picture

MEINOX Pharma Technologies

Working on a new way to stop cancer 
 Terms & Conditions

Contact Us

  • Home
  • Technology
    • Pipeline
    • Publications
    • Patents
    • MEISi Products
    • RUO Products >
      • MEISi-1
      • MEISi-2
      • hCAIIi-1
      • hCAIIi-2
      • hCAIIi-3
      • Meinox Small Molecule Library
      • Pathonex
      • ProteinX
  • News
  • About Us
    • Careers
    • Investors
    • Partners
  • Contact